tag:blogger.com,1999:blog-2080506270244832638.post6181804251929121141..comments2024-03-28T07:17:13.573-05:00Comments on Clark Street Value: Mereo BioPharma: Activist Proxy FightMDChttp://www.blogger.com/profile/10679835609782815537noreply@blogger.comBlogger13125tag:blogger.com,1999:blog-2080506270244832638.post-58626333671057652682024-01-26T18:29:13.705-06:002024-01-26T18:29:13.705-06:00Looking at Rubric's old valuation again, it is...Looking at Rubric's old valuation again, it is really only for Setrusumab, it seems like the market is excited about Alvelestat which is similar to INBRX-101 that SNY just paid $1.8+B for earlier this week. It appears MREO owns the rights to Alvelestat and said in their update earlier in January that they were looking for a development/commercial partner and would update the market this year. Anything close to the INBRX-101 would be ridiculous for MREO. But again, its science, outside my comfort zone, but I'm trying to rationalize holding here.MDChttps://www.blogger.com/profile/10679835609782815537noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-21186322704857935842024-01-22T13:53:52.577-06:002024-01-22T13:53:52.577-06:00I'm trying to just hold it, but you're rig...I'm trying to just hold it, but you're right, at a certain point its a science bet and I do try to stay away from those. Trying to balance some risk management with also giving a potential bigger winner some room to run and compound for me. Its tough when you have little to no knowledge of their assets like I do.MDChttps://www.blogger.com/profile/10679835609782815537noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-34961772107755428142024-01-22T13:10:47.693-06:002024-01-22T13:10:47.693-06:00The price is getting close to Rubric’s old valuati...The price is getting close to Rubric’s old valuation, which is starting to make this more and more a bet on the science. At what point do you close the bet? though there’s confidence so long as Rubric keeps buying.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-13597744000162988622023-10-18T17:23:33.797-05:002023-10-18T17:23:33.797-05:00Seems that Setrusumab valuation was not overstated...Seems that Setrusumab valuation was not overstated due to the movements nowadays. New valuation target? Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-8486553831150707212022-12-25T05:19:50.141-06:002022-12-25T05:19:50.141-06:00Can’t find any data on the 30% sales, could you pl...Can’t find any data on the 30% sales, could you please point me to a source?Widr5189noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-39616767335121432672022-12-19T15:32:08.202-06:002022-12-19T15:32:08.202-06:00Not really, no, we haven't gotten a lot of new...Not really, no, we haven't gotten a lot of new info since Rubric gained board seats.MDChttps://www.blogger.com/profile/10679835609782815537noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-13246370219971648012022-12-19T13:59:59.691-06:002022-12-19T13:59:59.691-06:00Any updated thoughts? Any updated thoughts? Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-65611238881555822312022-12-06T10:16:12.148-06:002022-12-06T10:16:12.148-06:00If Rosen was fighting and won board seats why be a...If Rosen was fighting and won board seats why be a seller of 30% of shares previous q? Tax selling? He own stock higher?Brendanhttps://www.blogger.com/profile/16672629257907418717noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-67734365528559250452022-11-08T08:54:49.089-06:002022-11-08T08:54:49.089-06:00Cash burn was a little higher than I anticipated. ...Cash burn was a little higher than I anticipated. It's going to be a volatile ride, but have some patience as Rubric is now on the board and can hopefully push their plan.MDChttps://www.blogger.com/profile/10679835609782815537noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-34529658517058817232022-11-03T22:23:22.741-05:002022-11-03T22:23:22.741-05:00any idea why the stock is down ~20% over the past ...any idea why the stock is down ~20% over the past two days? just bad earnings or something more menacing? Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-34089787599667159012022-10-28T09:18:28.044-05:002022-10-28T09:18:28.044-05:00https://www.sec.gov/Archives/edgar/data/1719714/00...https://www.sec.gov/Archives/edgar/data/1719714/000119312522271744/d403736dex991.htm<br /><br />Rubric and Mereo come to settlement agreement, Rubric gets 4 of the 5 board members they were asking for, minus David Rosen. Hopefully that means a monetization strategy is the go forward path.MDChttps://www.blogger.com/profile/10679835609782815537noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-66538454666902454512022-10-20T14:16:55.561-05:002022-10-20T14:16:55.561-05:00My guess is that management knows they're goin...My guess is that management knows they're going to lose the proxy contest and gave one last attempt to come to an agreement with Rubric to avoid it.MDChttps://www.blogger.com/profile/10679835609782815537noreply@blogger.comtag:blogger.com,1999:blog-2080506270244832638.post-84716694956178721682022-10-18T20:12:59.294-05:002022-10-18T20:12:59.294-05:00Any thoughts on today's MREO announcement (htt...Any thoughts on today's MREO announcement (https://www.marketwatch.com/press-release/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value-2022-10-18?siteid=bigcharts&dist=bigcharts&tesla=y) and Rubric's response (https://www.marketwatch.com/press-release/rubric-capital-management-comments-on-mereo-biopharma-updated-operating-plan-2022-10-18?siteid=bigcharts&dist=bigcharts&tesla=y)? Thanks. Anonymousnoreply@blogger.com